Novartis announced on January 6 that it had entered into an option agreement with two small pharmaceutical companies to license two cardiovascular drugs. About NovartisNovartis offers innovative healthcare solutions that meet the changing needs of patients and companies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these requirements: innovative drugs, cost-saving generic drugs, biosimilar pharmaceuticals and eye care. Novartis is the world leader in each of these areas. In 2016, the group had net sales of $48.5 billion, while research and development across the group was about $9.0 billion. Novartis Group companies employ approximately 118,000 full-time equivalents. Novartis products are sold in approximately 155 countries around the world. For more information, see www.novartis.com. Molecular Partners AG, a clinical-stage biotechnology company developing a new class of custom anti® drugs, known as DARPin®-Therapeutics, and Novartis AG, announced that they have entered into an option and licensing agreement to cooperate in the development, production and commercialization of the anti-COVID-19 DARPin program® of Molecular Partners. Ionis and Akcea said in a press release that they were entitled to receive $225 million in short-term payments, including an immediate down payment of $75 million and a US$100 million stake in Ionis. As part of the agreement, Novartis will pay a $50 million down payment to Conatus.
Any additional exercise fee is paid to Conatus after certain criteria, such as defined in the option, cooperation and licensing agreement, including required antitrust authorizations, have been met. As part of the agreement, IFM Due receives firm payments from Novartis to fully fund research and development costs related to the CGA S/STING program. JERUSALEM, 11.12.2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the company”) today announced the end of the feasibility and option agreement with Novartis for the development of a custom-made Accordion® Pill (AP) for a Novartis proprietary connection, although the AP has complied with technical and pharmacokinetic specifications (PK). Novartis informed Intec, after an internal and revised strategic evaluation, that the program no longer met Novartis` medium- and long-term strategic objectives. Novartis agreed to pay US$1.5 million to Intec Pharma at the end of the program. Novartis is on Twitter. Sign up to follow the multimedia content @Novartis to twitter.com/novartisFor Novartis, please see www.novartis.com/news/media-libraryFor questions on the website or the necessary registration, Please contact [email protected] Disclaimer The above publication contains forward-looking statements that are used by words such as “option,” “growth,” “portfolio,” “initiated,” “expected,” “expected” until 2020, “potential,” “potential,” “forward,” “test,” “review,” “fast-track term,” “may,” “may” or can be identified.
either through explicit or tacit discussions about possible approvals for Emricasan and THE FXR agonists developed internally by Novartis, or as individual agents, or in association with cenicriviroc, in association with THE FXR agonists developed in-house by Novartis, or with respect to potential future revenues from the emricasan and Agonists of the FXR, which are developed internally by Novartis , either as individual agents or in association, or cenicriviroc in association with FXR agonists developed in-house by Novartis, or with respect to the exercise of the licensing option for emricasan, or with regard to the objectives and objectives of collaboration with Conatus and the license for emricasan, and clinical cooperation with Allgan.